Scemblix Dosage
Generic name: ASCIMINIB HYDROCHLORIDE 20mg
Dosage form: tablet, film coated
Drug class: BCR-ABL tyrosine kinase inhibitors
Medically reviewed by Drugs.com. Last updated on Oct 29, 2024.
2.1 Recommended Dosage in Patients with Newly Diagnosed or Previously Treated Ph+ CML-CP
The recommended dose of SCEMBLIX is 80 mg taken orally once daily at approximately the same time each day or 40 mg orally twice daily at approximately 12-hour intervals. The recommended dose of SCEMBLIX is taken orally without food. Avoid food consumption for at least 2 hours before and 1 hour after taking SCEMBLIX.
Continue treatment with SCEMBLIX as long as clinical benefit is observed or until unacceptable toxicity occurs.
2.2 Recommended Dosage in Patients with Ph+ CML-CP with the T315I Mutation
The recommended dose of SCEMBLIX is 200 mg taken orally twice daily at approximately 12-hour intervals. The recommended dose of SCEMBLIX is taken orally without food. Avoid food consumption for at least 2 hours before and 1 hour after taking SCEMBLIX.
2.3 Missed Dose
Once Daily Dosage Regimen: If a SCEMBLIX dose is missed by more than approximately 12 hours, skip the dose and take the next dose as scheduled.
Twice Daily Dosage Regimens: If a SCEMBLIX dose is missed by more than approximately 6 hours, skip the dose and take the next dose as scheduled.
2.4 Dosage Modifications
Dosage Modifications for Patients with Newly Diagnosed or Previously Treated Ph+ CML-CP
For the management of adverse reactions, reduce the SCEMBLIX dose as described in Table 1.
Dosage Modifications for Patients with Ph+ CML-CP with the T315I Mutation
For the management of adverse reactions, reduce the SCEMBLIX dose as described in Table 1.
Dosage reduction | Dosage for Patients with newly diagnosed or previously treated Ph+ CML-CP | Dosage for patients with Ph+ CML-CP with the T315I mutation |
First |
|
160 mg twice daily |
Subsequent reduction | Permanently discontinue SCEMBLIX in patients unable to tolerate 40 mg once daily OR 20 mg twice daily. | Permanently discontinue SCEMBLIX in patients unable to tolerate 160 mg twice daily. |
The recommended dosage modifications for the management of selected adverse reactions are shown in Table 2.
Abbreviations: ANC, absolute neutrophil count; PLT, platelets; ULN, upper limit of normal. aBased on Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. |
|
Adverse reaction | Dosage modification |
Thrombocytopenia and/or neutropenia | |
ANC less than 1 x 109/L and/or PLT less than 50 x 109/L | Withhold SCEMBLIX until resolved to ANC greater than or equal to 1 x 109/L and/or PLT greater than or equal to 50 x 109/L. If resolved:
|
Asymptomatic amylase and/or lipase elevation | |
Elevation greater than 2 x ULN | Withhold SCEMBLIX until resolved to less than 1.5 x ULN. If resolved:
|
Non-hematologic adverse reactions | |
Grade 3a or higher | Withhold SCEMBLIX until recovery to Grade 1 or less. If resolved:
|
More about Scemblix (asciminib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: BCR-ABL tyrosine kinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Tasigna
Tasigna (nilotinib) is used to treat Philadelphia chromosome positive chronic myeloid leukemia ...
Bosulif
Bosulif is a kinase inhibitor that may be used to treat adults and some children aged 1 year and ...
Dasatinib
Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.